Pliant Therapeutics (PLRX) said Thursday that its board of directors has approved a limited duration shareholder rights agreement.
The company said the move is in response to recent open market accumulation of its common stock and is intended to prevent any attempt to gain control of the company without its approval.
Under the rights agreement, set to expire on March 11, 2026, Pliant said it will issue one preferred share purchase right for each outstanding share to stockholders of record as of March 25.
Shares of Pliant were up nearly 2% in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.